Eric Barret1, Baris Turkbey2, Philippe Puech3, Matthieu Durand4, Valeria Panebianco5, Jurgen J Fütterer6, Raphaële Renard-Penna7, Olivier Rouvière8. 1. Department of Urology, Institut Montsouris, Paris, France. eric.barret@imm.fr. 2. Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 3. Department of Radiology, CHU Lille, University of Lille, Lille, France. 4. Department of Urology, CHU Nice, Nice, France. 5. Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy. 6. Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. 7. Academic Department of Radiology, Hopital Tenon-Hopital Pitié-Salpétrière, AP-HP, UPMC Univ Paris 06, Paris, France. 8. Department of Urinary and Vascular Imaging, Hospices Civils de Lyon, Hôpital Edouard Herriot, University Lyon 1, Lyon, France.
Abstract
INTRODUCTION: Prostate cancer (PCa) imaging is a rapidly evolving field. Dramatic improvements in prostate MRI during the last decade will probably change the accuracy of diagnosis. This chapter reviews recent current evidence about MRI diagnostic performance and impact on PCa management. MATERIALS AND METHODS: The International Consultation on Urological Diseases nominated a committee to review the literature on prostate MRI. A search of the PubMed database was conducted to identify articles focussed on MP-MRI detection and staging protocols, reporting and scoring systems, the role of MP-MRI in diagnosing PCa prior to biopsy, in active surveillance, in focal therapy and in detecting local recurrence after treatment. RESULTS: Differences in opinion were reported in the use of the strength of magnets [1.5 Tesla (T) vs. 3T] and coils. More agreement was found regarding the choice of pulse sequences; diffusion-weighted MRI (DW-MRI), dynamic contrast-enhanced MRI (DCE MRI), and/or MR spectroscopy imaging (MRSI) are recommended in addition to conventional T2-weighted anatomical sequences. In 2015, the Prostate Imaging Reporting and Data System (PI-RADS version 2) was described to standardize image acquisition and interpretation. MP-MRI improves detection of clinically significant PCa (csPCa) in the repeat biopsy setting or before the confirmatory biopsy in patients considering active surveillance. It is useful to guide focal treatment and to detect local recurrences after treatment. Its role in biopsy-naive patients or during the course of active surveillance remains debated. CONCLUSION: MP-MRI is increasingly used to improve detection of csPCa and for the selection of a suitable therapeutic approach.
INTRODUCTION:Prostate cancer (PCa) imaging is a rapidly evolving field. Dramatic improvements in prostate MRI during the last decade will probably change the accuracy of diagnosis. This chapter reviews recent current evidence about MRI diagnostic performance and impact on PCa management. MATERIALS AND METHODS: The International Consultation on Urological Diseases nominated a committee to review the literature on prostate MRI. A search of the PubMed database was conducted to identify articles focussed on MP-MRI detection and staging protocols, reporting and scoring systems, the role of MP-MRI in diagnosing PCa prior to biopsy, in active surveillance, in focal therapy and in detecting local recurrence after treatment. RESULTS: Differences in opinion were reported in the use of the strength of magnets [1.5 Tesla (T) vs. 3T] and coils. More agreement was found regarding the choice of pulse sequences; diffusion-weighted MRI (DW-MRI), dynamic contrast-enhanced MRI (DCE MRI), and/or MR spectroscopy imaging (MRSI) are recommended in addition to conventional T2-weighted anatomical sequences. In 2015, the Prostate Imaging Reporting and Data System (PI-RADS version 2) was described to standardize image acquisition and interpretation. MP-MRI improves detection of clinically significant PCa (csPCa) in the repeat biopsy setting or before the confirmatory biopsy in patients considering active surveillance. It is useful to guide focal treatment and to detect local recurrences after treatment. Its role in biopsy-naive patients or during the course of active surveillance remains debated. CONCLUSION: MP-MRI is increasingly used to improve detection of csPCa and for the selection of a suitable therapeutic approach.
Entities:
Keywords:
Multiparametric MRI; Prostate; Prostate MRI; Prostate cancer
Authors: Marieke van Son; Max Peters; Marinus Moerland; Linda Kerkmeijer; Jan Lagendijk; Jochem van der Voort van Zyp Journal: Cancers (Basel) Date: 2018-12-03 Impact factor: 6.639